Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 8 de 8
Filter
1.
Tob Control ; 2024 Apr 26.
Article in English | MEDLINE | ID: mdl-38670795

ABSTRACT

The Population Assessment of Tobacco and Health (PATH) Study is a nationally representative, longitudinal study of the US population on tobacco use and its effects on health, collecting data annually since 2013. The COVID-19 pandemic interrupted in-person survey data collections around the world. In the USA, this included a PATH Study data collection focused on youth (13-17) and young adults (18-19) as well as other US surveys on tobacco use. Given that it was necessary to pause data collection and considering that tobacco-use behaviours could be expected to change along with pandemic-related changes in the social environment, the original design for the 2020 PATH Study data collection for youth and young adults was modified. Also, the PATH Study Adult Telephone Survey was developed to address the need for adult tobacco use monitoring in this unprecedented time. This article describes the modifications made to the 2020 PATH Study design and protocol to provide nationally representative data for youth and adults after the onset of the COVID-19 pandemic as well as the implications of these modifications for researchers.

2.
Tob Control ; 2023 May 31.
Article in English | MEDLINE | ID: mdl-37258274

ABSTRACT

The Population Assessment of Tobacco and Health (PATH) Study is a nationally representative study of the US population on tobacco use and its effects on health, with four waves of data collection between 2013 and 2017. Prior work described the methods of the first three waves. In this paper, we describe the methods of Wave 4, during which a replenishment sample was added to the ongoing cohort. We describe the design and estimation methods of the continuing Wave 1 cohort (with four waves of data) and the Wave 4 cohort (the new cohort created at Wave 4). We provide survey quality metrics, including response rates for both cohorts and a panel conditioning analysis, and guidance on understanding the target populations for both cohorts.

3.
Cancer Causes Control ; 32(10): 1129-1148, 2021 Oct.
Article in English | MEDLINE | ID: mdl-34292440

ABSTRACT

PURPOSE: The etiology of young-onset breast cancer (BC) is poorly understood, despite its greater likelihood of being hormone receptor-negative with a worse prognosis and persistent racial and socioeconomic inequities. We conducted a population-based case-control study of BC among young Black and White women and here discuss the theory that informed our study, exposures collected, study methods, and operational results. METHODS: Cases were non-Hispanic Black (NHB) and White (NHW) women age 20-49 years with invasive BC in metropolitan Detroit and Los Angeles County SEER registries 2010-2015. Controls were identified through area-based sampling from the U.S. census and frequency matched to cases on study site, race, and age. An eco-social theory of health informed life-course exposures collected from in-person interviews, including socioeconomic, reproductive, and energy balance factors. Measured anthropometry, blood (or saliva), and among cases SEER tumor characteristics and tumor tissue (from a subset of cases) were also collected. RESULTS: Of 5,309 identified potentially eligible cases, 2,720 sampled participants were screened and 1,812 completed interviews (682 NHB, 1140 NHW; response rate (RR): 60%). Of 24,612 sampled control households 18,612 were rostered, 2,716 participants were sampled and screened, and 1,381 completed interviews (665 NHB, 716 NHW; RR: 53%). Ninety-nine% of participants completed the main interview, 82% provided blood or saliva (75% blood only), and SEER tumor characteristics (including ER, PR and HER2 status) were obtained from 96% of cases. CONCLUSIONS: Results from the successfully established YWHHS should expand our understanding of young-onset BC etiology overall and by tumor type and identify sources of racial and socioeconomic inequities in BC.


Subject(s)
Breast Neoplasms , Adult , Black or African American , Breast Neoplasms/epidemiology , Case-Control Studies , Female , Humans , Incidence , Middle Aged , White People , Young Adult
4.
Cancer Causes Control ; 22(11): 1537-44, 2011 Nov.
Article in English | MEDLINE | ID: mdl-21866373

ABSTRACT

OBJECTIVE: Renal cell carcinoma (RCC) incidence is higher among blacks than whites in the United States and has been associated with the frequency and timing of childbirth among women in some epidemiologic studies. We investigated whether reproductive factors are associated with RCC, overall and by race, within a population-based case-control study. METHODS: Between 2002 and 2007, 497 female cases of incident RCC (136 black, 361 white) and 546 female controls (273 black, 273 white) within the Detroit and Chicago metropolitan areas were enrolled. Information on reproductive history and other factors was collected through in-person interviews. Multivariate-adjusted odds ratios (OR) and 95% confidence intervals (CI) were computed using unconditional logistic regression. RESULTS: Reduced RCC risk was observed among women aged ≥30 years at first live birth, relative to an age of <20 years (OR 0.5, 95% CI 0.3-0.9). This association was present among both white (OR 0.4, 95% CI 0.2-0.9) and, though not statistically significant, black women (OR 0.6, 95% CI 0.2-1.8). In analyses restricted to clear cell adenocarcinoma, the most common RCC histological subtype, the association was particularly strong (OR 0.3, 95% CI 0.2-0.8). We did not observe clear evidence of association with RCC for other reproductive factors. CONCLUSIONS: Our findings further support an association between late maternal age at first birth and reduced RCC risk, and suggest that the association may be particularly strong for clear cell adenocarcinoma.


Subject(s)
Black or African American , Carcinoma, Renal Cell/ethnology , Carcinoma, Renal Cell/epidemiology , Kidney Neoplasms/ethnology , Kidney Neoplasms/epidemiology , Reproductive History , White People , Adult , Aged , Aged, 80 and over , Case-Control Studies , Female , Humans , Incidence , Middle Aged , Risk Factors , United States/epidemiology , Young Adult
5.
Epidemiology ; 22(6): 797-804, 2011 Nov.
Article in English | MEDLINE | ID: mdl-21881515

ABSTRACT

BACKGROUND: Renal cell carcinoma and hypertension (a well-established renal cancer risk factor) are both more frequent among blacks than whites in the United States. The association between hypertension and renal cell carcinoma has not been examined in black Americans. We investigated the hypertension-renal cancer association by race, and we assessed the role of hypertension in the racial disparity of renal cancer incidence. METHODS: Participants were enrolled in a population-based case-control study in Detroit and Chicago during 2002-2007 (number of cases: 843 whites, 358 blacks; number of controls: 707 whites, 519 blacks). Participants reported their history of hypertension and antihypertensive drug use. We used unconditional logistic regression to calculate odds ratios (ORs) and 95% confidence intervals (CIs), adjusted for demographic characteristics, smoking, body mass index, and family history of cancer. RESULTS: Hypertension doubled renal cancer risk (OR = 2.0 [CI = 1.7-2.5]) overall. For whites, the OR was 1.9 (CI = 1.5-2.4), whereas for blacks it was 2.8 (2.1-3.8) (P for interaction = 0.11). ORs increased with time after hypertension diagnosis (P for trend <0.001), reaching 4.1 (CI = 2.3-7.4) for blacks and 2.6 (CI = 1.7-4.1) for whites after 25 years. ORs for poorly controlled hypertension were 4.5 (CI = 2.3-8.8) for blacks and 2.1 (CI = 1.2-3.8) for whites. If these estimates correctly represent causal effects and if, hypothetically, hypertension could be prevented entirely among persons aged 50-79 years, the black/white disparity in renal cancer could be reversed among women and reduced by two-thirds among men. CONCLUSIONS: Hypertension is a risk factor for renal cancer among both blacks and whites, and might explain a substantial portion of the racial disparity in renal cancer incidence. Preventing and controlling hypertension might reduce renal cancer incidence, adding to the known benefits of blood pressure control for heart disease and stroke reduction, particularly among blacks.


Subject(s)
Black People/statistics & numerical data , Carcinoma, Renal Cell/etiology , Hypertension/complications , Kidney Neoplasms/etiology , White People/statistics & numerical data , Adult , Age Factors , Aged , Antihypertensive Agents/therapeutic use , Carcinoma, Renal Cell/epidemiology , Case-Control Studies , Confidence Intervals , Female , Health Status Disparities , Humans , Hypertension/drug therapy , Hypertension/epidemiology , Incidence , Kidney Neoplasms/epidemiology , Logistic Models , Male , Middle Aged , Odds Ratio , Risk Factors , Sex Factors , United States/epidemiology , Young Adult
6.
Tob Regul Sci ; 7(1): 3-16, 2021 Jan.
Article in English | MEDLINE | ID: mdl-33860066

ABSTRACT

OBJECTIVES: The Population Assessment of Tobacco and Health (PATH) Study is a nationally representative study of the US population on tobacco use and its effects on health, with 3 waves of data collection between 2013 and 2016. Prior work described the methods of the first wave. In this paper, we describe the methods of the subsequent 2 waves and provide recommendations for how to conduct longitudinal analyses of PATH Study data. METHODS: We use standard survey quality metrics to evaluate the results of the follow-up waves of the PATH Study. The recommendations and examples of longitudinal and cross-sectional analyses of PATH Study data follow a design-based statistical inference framework. RESULTS: The quality metrics indicate that the PATH Study sample of approximately 40,000 continuing respondents remains representative of its target population. Depending on the intended analysis, different survey weights may be appropriate. CONCLUSION: The PATH Study data are a valuable resource for regulatory scientists interested in longitudinal analysis of tobacco use and its effects on health. The availability of multiple sets of specialized survey weights enables researchers to target a wide range of tobacco-related analytic questions.

7.
Eval Health Prof ; 36(3): 296-329, 2013 Sep.
Article in English | MEDLINE | ID: mdl-23975759

ABSTRACT

A sample frame is the listing of the units from which a sample is to be selected. When deciding upon a file to serve as a source for a sample frame for a survey, perhaps the most important consideration is the extent to which the target population will be covered by the frame. However, other issues also come into play such as the accuracy of contact and other information appearing on the file as well as its cost. The American Medical Association Masterfile has long been considered the preferred choice for surveys of physicians, although it does have drawbacks. Here we consider two alternative files, discussing their relative advantages and disadvantages. For surveys of physician practices (or other organizations that employ physicians), there have been no files that are obvious choices to serve as the basis for a sample frame. Here we discuss data collection on physician practices from an analytic perspective and consider how sampling physicians to obtain practice level data may be a desirable approach.


Subject(s)
Health Care Surveys/methods , Physicians , Professional Practice , Research Design , American Medical Association , Databases, Factual/statistics & numerical data , Humans , Medicine/classification , Medicine/statistics & numerical data , Physicians/statistics & numerical data , Sampling Studies , United States
8.
Am J Epidemiol ; 155(8): 771-5, 2002 Apr 15.
Article in English | MEDLINE | ID: mdl-11943696

ABSTRACT

The recent article, "Comparison of Telephone Sampling and Area Sampling: Response Rates and Within-Household Coverage" (Am J Epidemiol 2001;153:1119-27), raised a number of issues related to two sampling methodologies that can be used for selecting population-based controls for case-control studies: random digit dialing (RDD) and area probability sampling. Some of these issues are discussed in this commentary in more detail to help in making sample design decisions, including the need to take the analysis plan into account when developing a sample design. Data from the paper are used to illustrate how the choice of sample design can affect analyses. Relative costs associated with the two methodologies as well as variance and bias concerns are also discussed in detail. Sample coverage issues, including those associated with list-assisted RDD, are considered, as are some advantages of the list-assisted approach. A discussion of the use of concurrent screening and sampling with an RDD approach as an alternative to periodically selecting fixed sample sizes is provided.


Subject(s)
Case-Control Studies , Patient Selection , Sample Size , Humans , Research Design
SELECTION OF CITATIONS
SEARCH DETAIL